Home » Conatus Raises $20 Million for Hepatitis C Studies

Conatus Raises $20 Million for Hepatitis C Studies

February 14, 2011

San Diego’s Conatus Pharmaceuticals, which specializes in developing drugs for liver disease and cancers, said it closed on a $20 million block of equity funding, which was led by a new investor, AgeChem Venture Fund of Montreal.
Xconomy

21Jan
Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits
26Jan
Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup
27Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
27Jan
FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations
09Feb
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19
10Feb
FDA Under the Biden Administration: What’s to Come and What It Will Mean

Conatus Raises $20 Million for Hepatitis C Studies

Upcoming Events

Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

Medical Device Clinical Trials in China: Latest Regulatory Developments

FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

FDA Under the Biden Administration: What’s to Come and What It Will Mean

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

Seno Medical Gets Premarket Approval for Breast Cancer Diagnostic

Moderna to Start New Trial Adding Third Shot of COVID-19 Vaccine

The Revised ICH E8: A Guide to New Clinical Trial Requirements